Ceftolozane-tazobactam + Meropenem — Competitive Intelligence Brief

Ceftolozane-tazobactam + Meropenem (Ceftolozane-tazobactam + Meropenem) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic combination. Area: Infectious Disease.

marketed Beta-lactam antibiotic combination Bacterial penicillin-binding proteins (PBPs); beta-lactamase inhibition Infectious Disease Small molecule

Target snapshot

Ceftolozane-tazobactam + Meropenem (Ceftolozane-tazobactam + Meropenem) — National University of Singapore. This combination inhibits bacterial cell wall synthesis through dual beta-lactam action (ceftolozane-tazobactam and meropenem) while tazobactam protects against beta-lactamase resistance.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ceftolozane-tazobactam + Meropenem TARGET	Ceftolozane-tazobactam + Meropenem	National University of Singapore	marketed	Beta-lactam antibiotic combination	Bacterial penicillin-binding proteins (PBPs); beta-lactamase inhibition
omeprazole plus amoxicillin	omeprazole plus amoxicillin	National Taiwan University Hospital	marketed	Proton pump inhibitor + beta-lactam antibiotic combination	Proton pump (H+/K+-ATPase) and bacterial cell wall (penicillin-binding proteins)
Ilaprazole + Amoxicillin	Ilaprazole + Amoxicillin	Il-Yang Pharm. Co., Ltd.	marketed	Proton pump inhibitor + Beta-lactam antibiotic combination	H+/K+-ATPase (ilaprazole); Bacterial cell wall peptidoglycan (amoxicillin)
Vonoprazan-Amoxicillin Dual Therapy	Vonoprazan-Amoxicillin Dual Therapy	Nanjing First Hospital, Nanjing Medical University	marketed	Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
Prednisolone and amoxicillin/clavulanate	Prednisolone and amoxicillin/clavulanate	University of Chicago	marketed	Corticosteroid + Beta-lactam antibiotic combination	Glucocorticoid receptor (prednisolone); Bacterial peptidoglycan cross-linking (amoxicillin); Beta-lactamase (clavulanate inhibition)
Pivmecillinam/augmentin	Pivmecillinam/augmentin	Radboud University Medical Center	marketed	Beta-lactam antibiotic combination	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Vonoprazan + amoxicillin	Vonoprazan + amoxicillin	The Third Xiangya Hospital of Central South University	marketed	Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic combination class)

1. Juan A. Arnaiz · 1 drug in this class
2. National University of Singapore · 1 drug in this class
3. Population Health Research Institute · 1 drug in this class
4. Radboud University Medical Center · 1 drug in this class
5. UPECLIN HC FM Botucatu Unesp · 1 drug in this class